Home-based self-management and cognitive training for brain tumor survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants who are survivors of non-glioblastoma brain cancer or tumors (service members, veterans, and civilians) will be referred by their oncology providers and enrolled at Dartmouth-Hitchcock. CA participants are randomized to receive the HOBSCOTCH-CA program immediately or after a 3-month waitlist, and the study lasts about six months in total. The intervention consists of a pre-program session plus eight weekly 45–60 minute one-on-one virtual sessions with a certified cognitive coach, with optional caregiver involvement to target caregiver burden and knowledge. Outcomes include participant quality of life, self-reported cognition, symptom measures, and caregiver burden and quality of life.

Why it matters

Who can join: the full rules

CA Participants will be referred to the study by their providers (Oncologist) who will be made aware of the study and inclusion/exclusion criteria. Inclusion Criteria 2. - 5. and Exclusion Criteria 1. - 3. will be confirmed by referring providers. Participants who learn about the study here and elsewhere will be instructed on how to confirm their eligibility with their provider.

Inclusion Criteria for CA Participant:

1. 18 + years
2. Service members, Veterans and civilians with a diagnosis of brain cancer (excluding glioblastoma)
3. Diagnosis of primary brain tumor with expected survival of 2 years or greater (e.g., low-grade glioma, oligodendroglioma, IDH mutant astrocytoma, meningioma) defined as the presence of a primary lesion on neuroimaging (CT or MRI), confirmed by histopathological examination (Note: some patients being treated for meningioma may be treated with radiotherapy without need for initial histopathologic confirmation)
4. Patients undergoing surgical and/or radiation therapy will have completed their treatment at least 3 months prior to being enrolled in trial (Note: patients receiving chemotherapy or other systemic therapy will be included)
5. Stable on all CNS acting medications for one month prior to enrollment
6. Subjective cognitive complaints
7. Literate and proficient in English
8. Internet access for the pre-session and Session 1 of the HOBSCOTCH-CA program; telephone access for sessions 2-8

Exclusion Criteria for CA Participant:

1. Presence of a neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease)
2. Acute psychiatric disorder or substance abuse
3. Patients with glioblastoma (GBM)

Inclusion Criteria for CA Participant Caregiver:

1. Age 18 +
2. Caregiver to a patient with a confirmed diagnosis of brain cancer/tumor survivor
3. CA Subject has given permission for their caregiver to participate
4. Literate and proficient in English
5. Internet access (for Pre-HOBSCOTCH and Session 1)
6. Telephone access (for Session 8)

Exclusion Criteria for CA Participant Caregiver:

1. Significant visual impairment precluding reading or writing
2. No reliable telephone or internet access

Where it's running

• Dartmouth-Health Lebanon
  Lebanon, New Hampshire, United States Recruiting

Study contacts

• Principal investigator: Elaine T Kiriakopoulos, MD, MPH, MSc — Dartmouth-Health/Dartmouth-Hitchcock, Dartmouth College
• Study coordinator: Sarah J. Kaden, BA
• Email: sarah.j.kaden@hitchcock.org
• Phone: 603-650-4225

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HOBSCOTCH-MS: Home-based telehealth cognitive coaching for people with multiple sclerosis

  This program will test whether a home-based telehealth cognitive coaching program (HOBSCOTCH-MS) can improve thinking, memory, and quality of life for people with MS and reduce caregiver burden.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT06951919

• Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06640582

• Comparing awake craniotomy and general anesthesia for glioblastoma surgery

  This study is testing whether having brain surgery while awake is safer and more effective than having it under general anesthesia for people with glioblastoma in important areas of the brain.

  Recruiting at 5 sites Erasmus Medical Center · Ghent and 4 other locations · NCT03861299

• Spatial scene memory testing for people with temporal lobe epilepsy having surgery

  This project tests whether a virtual tour memory task combined with brain recordings can show how adults with temporal lobe epilepsy recognize and recall places.

  Recruiting at 2 sites University of California, Davis · Sacramento, California and 1 other locations · NCT07580183

• Panitumumab-IRDye800 for guiding brain tumor surgery

  A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07493447

• Meningioma: How social factors and personal risks relate to health outcomes

  This study tests whether social and personal risk factors help explain differences in health outcomes for adults with meningioma.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07418775

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.